Overview

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness and safety of IONIS-FB-LRx, an antisense inhibitor of complement factor B messenger ribonucleic acid (CFB mRNA), and to evaluate the effect of IONIS-FB-LRx on plasma factor B (FB) levels and serum AH50, CH50 activity in participants with primary immunoglobulin A (IgA) nephropathy.

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.

Treatments:

Complement Factor B
Complement System Proteins